Cargando…

Molecular Characteristics of Radon Associated Lung Cancer Highlights MET Alterations

SIMPLE SUMMARY: Lung cancer (LC) is the leading cause of cancer death worldwide. After smoking, one of the most prominent risk factors for LC development is radon (Rn) exposure. In our study we analysed and compared the genetic landscape of LC patients from a Rn exposed village with local matched no...

Descripción completa

Detalles Bibliográficos
Autores principales: Gamerith, Gabriele, Kloppenburg, Marcel, Mildner, Finn, Amann, Arno, Merkelbach-Bruse, Sabine, Heydt, Carina, Siemanowski, Janna, Buettner, Reinhard, Fiegl, Michael, Manzl, Claudia, Pall, Georg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600309/
https://www.ncbi.nlm.nih.gov/pubmed/36291897
http://dx.doi.org/10.3390/cancers14205113
_version_ 1784816810081648640
author Gamerith, Gabriele
Kloppenburg, Marcel
Mildner, Finn
Amann, Arno
Merkelbach-Bruse, Sabine
Heydt, Carina
Siemanowski, Janna
Buettner, Reinhard
Fiegl, Michael
Manzl, Claudia
Pall, Georg
author_facet Gamerith, Gabriele
Kloppenburg, Marcel
Mildner, Finn
Amann, Arno
Merkelbach-Bruse, Sabine
Heydt, Carina
Siemanowski, Janna
Buettner, Reinhard
Fiegl, Michael
Manzl, Claudia
Pall, Georg
author_sort Gamerith, Gabriele
collection PubMed
description SIMPLE SUMMARY: Lung cancer (LC) is the leading cause of cancer death worldwide. After smoking, one of the most prominent risk factors for LC development is radon (Rn) exposure. In our study we analysed and compared the genetic landscape of LC patients from a Rn exposed village with local matched non-exposed patients. Within the concordant genetic landscape, an increase in genetic MET proto-oncogene, receptor tyrosine kinase (MET) alteration in the Rn-exposed cohort was monitored, underlining the importance of routine MET testing and potential to enable a more effective treatment for this specific subgroup. ABSTRACT: Effective targeted treatment strategies resulted from molecular profiling of lung cancer with distinct prevalent mutation profiles in smokers and non-smokers. Although Rn is the second most important risk factor, data for Rn-dependent driver events are limited. Therefore, a Rn-exposed cohort of lung cancer patients was screened for oncogenic drivers and their survival and genetic profiles were compared with data of the average regional population. Genetic alterations were analysed in 20 Rn-exposed and 22 histologically matched non-Rn exposed LC patients using targeted Next generation sequencing (NGS) and Fluorescence In Situ Hybridization (FISH). Sufficient material and sample quality could be obtained in 14/27 non-exposed versus 17/22 Rn-exposed LC samples. Survival was analysed in comparison to a histologically and stage-matched regional non-exposed lung cancer cohort (n = 51) for hypothesis generating. Median overall survivals were 83.02 months in the Rn-exposed and 38.7 months in the non-exposed lung cancer cohort (p = 0.22). Genetic alterations of both patient cohorts were in high concordance, except for an increase in MET alterations and a decrease in TP53 mutations in the Rn-exposed patients in this small hypothesis generating study.
format Online
Article
Text
id pubmed-9600309
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96003092022-10-27 Molecular Characteristics of Radon Associated Lung Cancer Highlights MET Alterations Gamerith, Gabriele Kloppenburg, Marcel Mildner, Finn Amann, Arno Merkelbach-Bruse, Sabine Heydt, Carina Siemanowski, Janna Buettner, Reinhard Fiegl, Michael Manzl, Claudia Pall, Georg Cancers (Basel) Article SIMPLE SUMMARY: Lung cancer (LC) is the leading cause of cancer death worldwide. After smoking, one of the most prominent risk factors for LC development is radon (Rn) exposure. In our study we analysed and compared the genetic landscape of LC patients from a Rn exposed village with local matched non-exposed patients. Within the concordant genetic landscape, an increase in genetic MET proto-oncogene, receptor tyrosine kinase (MET) alteration in the Rn-exposed cohort was monitored, underlining the importance of routine MET testing and potential to enable a more effective treatment for this specific subgroup. ABSTRACT: Effective targeted treatment strategies resulted from molecular profiling of lung cancer with distinct prevalent mutation profiles in smokers and non-smokers. Although Rn is the second most important risk factor, data for Rn-dependent driver events are limited. Therefore, a Rn-exposed cohort of lung cancer patients was screened for oncogenic drivers and their survival and genetic profiles were compared with data of the average regional population. Genetic alterations were analysed in 20 Rn-exposed and 22 histologically matched non-Rn exposed LC patients using targeted Next generation sequencing (NGS) and Fluorescence In Situ Hybridization (FISH). Sufficient material and sample quality could be obtained in 14/27 non-exposed versus 17/22 Rn-exposed LC samples. Survival was analysed in comparison to a histologically and stage-matched regional non-exposed lung cancer cohort (n = 51) for hypothesis generating. Median overall survivals were 83.02 months in the Rn-exposed and 38.7 months in the non-exposed lung cancer cohort (p = 0.22). Genetic alterations of both patient cohorts were in high concordance, except for an increase in MET alterations and a decrease in TP53 mutations in the Rn-exposed patients in this small hypothesis generating study. MDPI 2022-10-19 /pmc/articles/PMC9600309/ /pubmed/36291897 http://dx.doi.org/10.3390/cancers14205113 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Gamerith, Gabriele
Kloppenburg, Marcel
Mildner, Finn
Amann, Arno
Merkelbach-Bruse, Sabine
Heydt, Carina
Siemanowski, Janna
Buettner, Reinhard
Fiegl, Michael
Manzl, Claudia
Pall, Georg
Molecular Characteristics of Radon Associated Lung Cancer Highlights MET Alterations
title Molecular Characteristics of Radon Associated Lung Cancer Highlights MET Alterations
title_full Molecular Characteristics of Radon Associated Lung Cancer Highlights MET Alterations
title_fullStr Molecular Characteristics of Radon Associated Lung Cancer Highlights MET Alterations
title_full_unstemmed Molecular Characteristics of Radon Associated Lung Cancer Highlights MET Alterations
title_short Molecular Characteristics of Radon Associated Lung Cancer Highlights MET Alterations
title_sort molecular characteristics of radon associated lung cancer highlights met alterations
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600309/
https://www.ncbi.nlm.nih.gov/pubmed/36291897
http://dx.doi.org/10.3390/cancers14205113
work_keys_str_mv AT gamerithgabriele molecularcharacteristicsofradonassociatedlungcancerhighlightsmetalterations
AT kloppenburgmarcel molecularcharacteristicsofradonassociatedlungcancerhighlightsmetalterations
AT mildnerfinn molecularcharacteristicsofradonassociatedlungcancerhighlightsmetalterations
AT amannarno molecularcharacteristicsofradonassociatedlungcancerhighlightsmetalterations
AT merkelbachbrusesabine molecularcharacteristicsofradonassociatedlungcancerhighlightsmetalterations
AT heydtcarina molecularcharacteristicsofradonassociatedlungcancerhighlightsmetalterations
AT siemanowskijanna molecularcharacteristicsofradonassociatedlungcancerhighlightsmetalterations
AT buettnerreinhard molecularcharacteristicsofradonassociatedlungcancerhighlightsmetalterations
AT fieglmichael molecularcharacteristicsofradonassociatedlungcancerhighlightsmetalterations
AT manzlclaudia molecularcharacteristicsofradonassociatedlungcancerhighlightsmetalterations
AT pallgeorg molecularcharacteristicsofradonassociatedlungcancerhighlightsmetalterations